JP2022523050A - 合理的設計により増強された新規なaavウイルスによる網膜における高効率の形質導入および側方への広がり - Google Patents
合理的設計により増強された新規なaavウイルスによる網膜における高効率の形質導入および側方への広がり Download PDFInfo
- Publication number
- JP2022523050A JP2022523050A JP2021543230A JP2021543230A JP2022523050A JP 2022523050 A JP2022523050 A JP 2022523050A JP 2021543230 A JP2021543230 A JP 2021543230A JP 2021543230 A JP2021543230 A JP 2021543230A JP 2022523050 A JP2022523050 A JP 2022523050A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- raav
- cells
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010361 transduction Methods 0.000 title description 49
- 230000026683 transduction Effects 0.000 title description 49
- 210000001525 retina Anatomy 0.000 title description 45
- 238000009510 drug design Methods 0.000 title description 2
- 239000002245 particle Substances 0.000 claims abstract description 104
- 210000004027 cell Anatomy 0.000 claims abstract description 102
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 84
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 47
- 241000124008 Mammalia Species 0.000 claims abstract description 31
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 18
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 18
- 239000002157 polynucleotide Substances 0.000 claims abstract description 18
- 208000017442 Retinal disease Diseases 0.000 claims abstract description 14
- 210000000608 photoreceptor cell Anatomy 0.000 claims abstract description 13
- 230000002463 transducing effect Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 45
- 230000014509 gene expression Effects 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 101710197658 Capsid protein VP1 Proteins 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 19
- 101710132601 Capsid protein Proteins 0.000 claims description 17
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims description 17
- 101710108545 Viral protein 1 Proteins 0.000 claims description 17
- 108090000565 Capsid Proteins Proteins 0.000 claims description 15
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 claims description 13
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 claims description 13
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 claims description 13
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 claims description 13
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 claims description 13
- 102100022663 Retinal guanylyl cyclase 1 Human genes 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 claims description 12
- 101710081079 Minor spike protein H Proteins 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 241000702421 Dependoparvovirus Species 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 230000006870 function Effects 0.000 claims description 9
- -1 antibody Proteins 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- 239000013608 rAAV vector Substances 0.000 claims description 7
- 101000611338 Homo sapiens Rhodopsin Proteins 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 230000008439 repair process Effects 0.000 claims description 5
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims description 5
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 102000004437 G-Protein-Coupled Receptor Kinase 1 Human genes 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 210000000873 fovea centralis Anatomy 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 208000032578 Inherited retinal disease Diseases 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 2
- 108091030071 RNAI Proteins 0.000 claims description 2
- 208000032430 Retinal dystrophy Diseases 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 201000006321 fundus dystrophy Diseases 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 230000003945 visual behavior Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 208000014674 injury Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 94
- 239000007924 injection Substances 0.000 abstract description 94
- 210000000234 capsid Anatomy 0.000 abstract description 42
- 239000005090 green fluorescent protein Substances 0.000 description 75
- 239000013598 vector Substances 0.000 description 69
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 34
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 28
- 108091008695 photoreceptors Proteins 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 27
- 230000002207 retinal effect Effects 0.000 description 25
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 25
- 150000001413 amino acids Chemical group 0.000 description 22
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 19
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 18
- 241000282553 Macaca Species 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 12
- 238000001415 gene therapy Methods 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000004445 quantitative analysis Methods 0.000 description 11
- 229940054733 arestin Drugs 0.000 description 10
- GLMUAFMGXXHGLU-VQAITOIOSA-N minocycline hydrochloride Chemical compound [H+].[Cl-].C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GLMUAFMGXXHGLU-VQAITOIOSA-N 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 238000012014 optical coherence tomography Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000004451 qualitative analysis Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 9
- 101710137010 Retinol-binding protein 3 Proteins 0.000 description 9
- 102100038247 Retinol-binding protein 3 Human genes 0.000 description 9
- 208000002352 blister Diseases 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 210000002763 pyramidal cell Anatomy 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102100039214 Guanine nucleotide-binding protein G(t) subunit alpha-2 Human genes 0.000 description 7
- 101000888142 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-2 Proteins 0.000 description 7
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 7
- 108090000526 Papain Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 229940055729 papain Drugs 0.000 description 7
- 235000019834 papain Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101150062267 Gucy2e gene Proteins 0.000 description 6
- 101100230371 Rattus norvegicus Gucy2d gene Proteins 0.000 description 6
- 208000014769 Usher Syndromes Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000004456 color vision Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000013607 AAV vector Substances 0.000 description 5
- 208000036443 AIPL1-related retinopathy Diseases 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 5
- 206010010356 Congenital anomaly Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102100028359 ADP-ribosylation factor-like protein 6 Human genes 0.000 description 4
- 102000003916 Arrestin Human genes 0.000 description 4
- 108090000328 Arrestin Proteins 0.000 description 4
- 102100035673 Centrosomal protein of 290 kDa Human genes 0.000 description 4
- 101710198317 Centrosomal protein of 290 kDa Proteins 0.000 description 4
- 102100029362 Cone-rod homeobox protein Human genes 0.000 description 4
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 4
- 108010078321 Guanylate Cyclase Proteins 0.000 description 4
- 102000014469 Guanylate cyclase Human genes 0.000 description 4
- 102100033969 Guanylyl cyclase-activating protein 1 Human genes 0.000 description 4
- 101000769028 Homo sapiens ADP-ribosylation factor-like protein 6 Proteins 0.000 description 4
- 101000919370 Homo sapiens Cone-rod homeobox protein Proteins 0.000 description 4
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 4
- 101000845196 Homo sapiens Tetratricopeptide repeat protein 8 Proteins 0.000 description 4
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 4
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100031271 Tetratricopeptide repeat protein 8 Human genes 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000938 luteal effect Effects 0.000 description 4
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 4
- 101150066583 rep gene Proteins 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102100022794 Bestrophin-1 Human genes 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 101150044789 Cap gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 3
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 3
- 201000008886 Leber congenital amaurosis 14 Diseases 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- 208000034247 Pattern dystrophy Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 3
- 102100040756 Rhodopsin Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102100024081 Aryl-hydrocarbon-interacting protein-like 1 Human genes 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100021295 Bardet-Biedl syndrome 1 protein Human genes 0.000 description 2
- 102100021296 Bardet-Biedl syndrome 10 protein Human genes 0.000 description 2
- 102100027883 Bardet-Biedl syndrome 2 protein Human genes 0.000 description 2
- 102100027884 Bardet-Biedl syndrome 4 protein Human genes 0.000 description 2
- 102100027878 Bardet-Biedl syndrome 5 protein Human genes 0.000 description 2
- 102100027882 Bardet-Biedl syndrome 7 protein Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100022509 Cadherin-23 Human genes 0.000 description 2
- 101000855645 Camptotheca acuminata (S)-8-oxocitronellyl enol synthase CYC2 Proteins 0.000 description 2
- 102100031060 Clarin-1 Human genes 0.000 description 2
- 206010010541 Congenital melanosis Diseases 0.000 description 2
- 102100029142 Cyclic nucleotide-gated cation channel alpha-3 Human genes 0.000 description 2
- 102100029141 Cyclic nucleotide-gated cation channel beta-1 Human genes 0.000 description 2
- 102100029140 Cyclic nucleotide-gated cation channel beta-3 Human genes 0.000 description 2
- 238000000116 DAPI staining Methods 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 102100032053 Elongation of very long chain fatty acids protein 4 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 2
- 108010014707 Guanylate Cyclase-Activating Proteins Proteins 0.000 description 2
- 102100033968 Guanylyl cyclase-activating protein 2 Human genes 0.000 description 2
- 102100037931 Harmonin Human genes 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 101000594506 Homo sapiens Acyl-coenzyme A diphosphatase NUDT19 Proteins 0.000 description 2
- 101000779572 Homo sapiens Alpha-protein kinase 3 Proteins 0.000 description 2
- 101000833576 Homo sapiens Aryl-hydrocarbon-interacting protein-like 1 Proteins 0.000 description 2
- 101000894722 Homo sapiens Bardet-Biedl syndrome 1 protein Proteins 0.000 description 2
- 101000894732 Homo sapiens Bardet-Biedl syndrome 10 protein Proteins 0.000 description 2
- 101000697700 Homo sapiens Bardet-Biedl syndrome 2 protein Proteins 0.000 description 2
- 101000697660 Homo sapiens Bardet-Biedl syndrome 4 protein Proteins 0.000 description 2
- 101000697666 Homo sapiens Bardet-Biedl syndrome 5 protein Proteins 0.000 description 2
- 101000697669 Homo sapiens Bardet-Biedl syndrome 7 protein Proteins 0.000 description 2
- 101000899442 Homo sapiens Cadherin-23 Proteins 0.000 description 2
- 101000992973 Homo sapiens Clarin-1 Proteins 0.000 description 2
- 101000771071 Homo sapiens Cyclic nucleotide-gated cation channel alpha-3 Proteins 0.000 description 2
- 101000771075 Homo sapiens Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 2
- 101000771083 Homo sapiens Cyclic nucleotide-gated cation channel beta-3 Proteins 0.000 description 2
- 101000921354 Homo sapiens Elongation of very long chain fatty acids protein 4 Proteins 0.000 description 2
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 2
- 101001068480 Homo sapiens Guanylyl cyclase-activating protein 1 Proteins 0.000 description 2
- 101001068475 Homo sapiens Guanylyl cyclase-activating protein 2 Proteins 0.000 description 2
- 101000805947 Homo sapiens Harmonin Proteins 0.000 description 2
- 101001011412 Homo sapiens IQ calmodulin-binding motif-containing protein 1 Proteins 0.000 description 2
- 101001044118 Homo sapiens Inosine-5'-monophosphate dehydrogenase 1 Proteins 0.000 description 2
- 101001047038 Homo sapiens Inward rectifier potassium channel 13 Proteins 0.000 description 2
- 101001008411 Homo sapiens Lebercilin Proteins 0.000 description 2
- 101001137074 Homo sapiens Long-wave-sensitive opsin 1 Proteins 0.000 description 2
- 101000573510 Homo sapiens McKusick-Kaufman/Bardet-Biedl syndromes putative chaperonin Proteins 0.000 description 2
- 101001120868 Homo sapiens Meckel syndrome type 1 protein Proteins 0.000 description 2
- 101001120864 Homo sapiens Meckelin Proteins 0.000 description 2
- 101000598987 Homo sapiens Medium-wave-sensitive opsin 1 Proteins 0.000 description 2
- 101000957756 Homo sapiens Microtubule-associated protein RP/EB family member 2 Proteins 0.000 description 2
- 101000996052 Homo sapiens Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Proteins 0.000 description 2
- 101000854060 Homo sapiens Oxygen-regulated protein 1 Proteins 0.000 description 2
- 101000610652 Homo sapiens Peripherin-2 Proteins 0.000 description 2
- 101000633511 Homo sapiens Photoreceptor-specific nuclear receptor Proteins 0.000 description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 2
- 101001062227 Homo sapiens Protein RD3 Proteins 0.000 description 2
- 101000781361 Homo sapiens Protein XRP2 Proteins 0.000 description 2
- 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 description 2
- 101001028804 Homo sapiens Protein eyes shut homolog Proteins 0.000 description 2
- 101000945390 Homo sapiens Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma Proteins 0.000 description 2
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 2
- 101000742938 Homo sapiens Retinol dehydrogenase 12 Proteins 0.000 description 2
- 101000670189 Homo sapiens Ribulose-phosphate 3-epimerase Proteins 0.000 description 2
- 101000628575 Homo sapiens Serine/threonine-protein kinase 19 Proteins 0.000 description 2
- 101000979098 Homo sapiens Serine/threonine-protein kinase MAK Proteins 0.000 description 2
- 101000652369 Homo sapiens Spermatogenesis-associated protein 7 Proteins 0.000 description 2
- 101000772173 Homo sapiens Tubby-related protein 1 Proteins 0.000 description 2
- 101000610557 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp31 Proteins 0.000 description 2
- 101000805941 Homo sapiens Usherin Proteins 0.000 description 2
- 101000666127 Homo sapiens Whirlin Proteins 0.000 description 2
- 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 description 2
- 101001104110 Homo sapiens X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Proteins 0.000 description 2
- 101000883219 Homo sapiens cGMP-gated cation channel alpha-1 Proteins 0.000 description 2
- 102100029842 IQ calmodulin-binding motif-containing protein 1 Human genes 0.000 description 2
- 102100021602 Inosine-5'-monophosphate dehydrogenase 1 Human genes 0.000 description 2
- 102100022843 Inward rectifier potassium channel 13 Human genes 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102100027443 Lebercilin Human genes 0.000 description 2
- 102100035576 Long-wave-sensitive opsin 1 Human genes 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 208000035719 Maculopathy Diseases 0.000 description 2
- 102100026300 McKusick-Kaufman/Bardet-Biedl syndromes putative chaperonin Human genes 0.000 description 2
- 102100026048 Meckel syndrome type 1 protein Human genes 0.000 description 2
- 102100026047 Meckelin Human genes 0.000 description 2
- 102100037812 Medium-wave-sensitive opsin 1 Human genes 0.000 description 2
- 101100069794 Mus musculus Gucy2e gene Proteins 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 108010009047 Myosin VIIa Proteins 0.000 description 2
- 102100034451 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102100040375 Peripherin-2 Human genes 0.000 description 2
- 102100029533 Photoreceptor-specific nuclear receptor Human genes 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100040120 Prominin-1 Human genes 0.000 description 2
- 102100029276 Protein RD3 Human genes 0.000 description 2
- 102100033154 Protein XRP2 Human genes 0.000 description 2
- 102100027331 Protein crumbs homolog 1 Human genes 0.000 description 2
- 102100037166 Protein eyes shut homolog Human genes 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 101710181452 Retinal guanylyl cyclase 1 Proteins 0.000 description 2
- 102100033597 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma Human genes 0.000 description 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 2
- 102100038054 Retinol dehydrogenase 12 Human genes 0.000 description 2
- 101001128051 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L3 Proteins 0.000 description 2
- 101000733871 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L4-A Proteins 0.000 description 2
- 101000733875 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L4-B Proteins 0.000 description 2
- 102100026757 Serine/threonine-protein kinase 19 Human genes 0.000 description 2
- 102100023230 Serine/threonine-protein kinase MAK Human genes 0.000 description 2
- 102100030257 Spermatogenesis-associated protein 7 Human genes 0.000 description 2
- 101000942604 Sphingomonas wittichii (strain DC-6 / KACC 16600) Chloroacetanilide N-alkylformylase, oxygenase component Proteins 0.000 description 2
- 102000006612 Transducin Human genes 0.000 description 2
- 108010087042 Transducin Proteins 0.000 description 2
- 102100029293 Tubby-related protein 1 Human genes 0.000 description 2
- 102100040118 U4/U6 small nuclear ribonucleoprotein Prp31 Human genes 0.000 description 2
- 102100031835 Unconventional myosin-VIIa Human genes 0.000 description 2
- 102100037930 Usherin Human genes 0.000 description 2
- 102100038102 Whirlin Human genes 0.000 description 2
- 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 description 2
- 102100040089 X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 201000011340 autosomal recessive nonsyndromic deafness 31 Diseases 0.000 description 2
- 208000035257 autosomal recessive nonsyndromic hearing loss 31 Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 102100038623 cGMP-gated cation channel alpha-1 Human genes 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000006754 cone-rod dystrophy Diseases 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 201000004502 glycogen storage disease II Diseases 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- 229960004359 iodixanol Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- LBCGUKCXRVUULK-QGZVFWFLSA-N n-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1h-imidazol-1-yl)-6-methylpyrimidin-4-yl]-d-prolinamide Chemical compound N=1C(C)=CC(N2[C@H](CCC2)C(=O)NCCC=2C=C3OCOC3=CC=2)=NC=1N1C=CN=C1 LBCGUKCXRVUULK-QGZVFWFLSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000956 olfactory bulb Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 239000000790 retinal pigment Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 1
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 1
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 108050002823 Bestrophin Proteins 0.000 description 1
- 102000012304 Bestrophin Human genes 0.000 description 1
- 208000009278 Blue cone monochromatism Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000862448 Chlorocebus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 108010003730 Cone Opsins Proteins 0.000 description 1
- 206010062328 Congenital cyst Diseases 0.000 description 1
- 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101100351286 Dictyostelium discoideum pdeE gene Proteins 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 101150066038 E4 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108091004242 G-Protein-Coupled Receptor Kinase 1 Proteins 0.000 description 1
- 208000036357 GUCY2D-related recessive retinopathy Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 101000858031 Homo sapiens Coxsackievirus and adenovirus receptor Proteins 0.000 description 1
- 101100230369 Homo sapiens GUCY2D gene Proteins 0.000 description 1
- 101000997017 Homo sapiens Neural retina-specific leucine zipper protein Proteins 0.000 description 1
- 101001072259 Homo sapiens Protocadherin-15 Proteins 0.000 description 1
- 101000829506 Homo sapiens Rhodopsin kinase GRK1 Proteins 0.000 description 1
- 101000609947 Homo sapiens Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha Proteins 0.000 description 1
- 101000609949 Homo sapiens Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Proteins 0.000 description 1
- 101000805943 Homo sapiens Usher syndrome type-1G protein Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 101000598988 Mus musculus Medium-wave-sensitive opsin 1 Proteins 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102100036382 Protocadherin-15 Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102100023742 Rhodopsin kinase GRK1 Human genes 0.000 description 1
- 108090000799 Rhodopsin kinases Proteins 0.000 description 1
- 108060007030 Ribulose-phosphate 3-epimerase Proteins 0.000 description 1
- 102100039270 Ribulose-phosphate 3-epimerase Human genes 0.000 description 1
- 102100039177 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha Human genes 0.000 description 1
- 102100039174 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Human genes 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 241001415849 Strigiformes Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102100037929 Usher syndrome type-1G protein Human genes 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 201000007728 blue cone monochromacy Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108010070387 guanylate cyclase 1 Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000045091 human NRL Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 238000011392 neighbor-joining method Methods 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 101150037969 pde-6 gene Proteins 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 230000004262 retinal health Effects 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本出願は、2019年1月23日に出願された米国仮出願第62/795,695号の出願日の利益を主張し、その内容全体は、参照により援用される。
この発明は、国立衛生研究所によって授与された認可番号R01 EY024280の下、政府の支援によりなされた。政府は発明において一定の権利を有する。
本発明は、一般的には分子生物学およびウイルス学の分野に、および具体的に言うと、網膜疾患の処置のための遺伝子治療ベクターおよび方法の開発に関する。
治療用遺伝子素材を送達するためにウイルスを使用することによって、遺伝子治療の分野における大きな前進が達成された。アデノ随伴ウイルスは、その低い免疫原性、および、非***細胞を効果的に形質導入させる能力に起因して、遺伝子治療に効果の高いウイルスベクターとして多大な注目を引きつけている。AAVは、様々な細胞および組織型を感染させることが示されており、および、このウイルス系をヒト遺伝子治療における使用のために適応させることに対して最近10年間にわたって有意な進歩が遂げられている。
AAVは、治療遺伝子を網膜へ標的化するための第一選択ベクターになっている。網膜指向性を発揮する天然由来と合成との両方のAAVが同定されている。近年、新規なAAVカプシド血清型44.9が、正常なアカゲザル腎臓細胞培養から取ったサルアデノウイルスSV15の研究所ストックから単離された。2016年11月17日に発行されたWO 2016/183297;2018年12月13日に発行された米国特許出願公開第2018/0355376号;およびNovel Adeno-Associated Virus for Gene Therapy, Fed. Reg. 80, 149 (Aug. 4, 2015)が参照され、それらの各々の全体が本明細書に援用される。AAV44.9は、唾液腺細胞、肝細胞、および多種のニューロン(例として、大脳皮質の細胞、嗅球、脳幹、および小脳のプルキンエ細胞)を包含する数多の細胞型を効率的に形質導入させる。
いくつかの態様において、rAAV粒子中の異種核酸配列は、診断または治療剤、例として、ポリペプチド、ペプチド、リボザイム、ペプチド核酸、siRNA、RNAi、アンチセンスオリゴヌクレオチド、アンチセンスポリヌクレオチド、抗体、抗原結合フラグメント、またはそれらのいずれかの組み合わせをコードする。
以下の図面は、本願明細書の一部を形成し、および、本発明のある側面をさらに示すために包含される。本発明は、似たような参照数字が似たような要素を同定する、添付の図面と併せて、以下の記載を参照することによって、より良く理解され得る:
本開示は、カプシド血清型AAV44.9の新規なバリアントであるAAV44.9(E531D)、ならびに、このプラスミドを組み込んだベクターおよび粒子の、ベンチマークのベクター(密接に関連するAAVrh.8および改良されていないAAV44.9)に対して相対的な、網膜下注射されたマウスおよびマカクにおけるベクターの性能の評価を提供する。本明細書に記載のとおり、両方の種において、AAV44.9(E531D)は、改良されていないAAV44.9およびAAVrh.8に対して相対的により高い網膜形質導入、および、ベンチマークのカプシド(例として、AAV5およびAAV8に基づいたベクター)よりも有意に高い形質導入を媒介するということが見いだされた。
MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEQSPQEPDSSSGIGKTGQQPAKKRLNFGQTGDTESVPDPQPLGEPPAAPSGLGPNTMASGGGAPMADNNEGADGVGNSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNEGTKTIANNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMVPQYGYLTLNNGSQALGRSSFYCLEYFPSQMLRTGNNFQFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLVRTQTTGTGGTQTLAFSQAGPSSMASQARNWVPGPSYRQQRVSTTTNQNNNSNFAWTGAAKFKLNGRDSLMNPGVAMASHKDDDDRFFPSSGVLIFGKQGAGNDGVDYSQVLITDEEEIKATNPVATEEYGAVAINNQAANTQAQTGLVHNQGVIPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPLTFNQAKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGVYSEPRPIGTRYLTRNL
MAPGKKRPVEQSPQEPDSSSGIGKTGQQPAKKRLNFGQTGDTESVPDPQPLGEPPAAPSGLGPNTMASGGGAPMADNNEGADGVGNSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNEGTKTIANNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMVPQYGYLTLNNGSQALGRSSFYCLEYFPSQMLRTGNNFQFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLVRTQTTGTGGTQTLAFSQAGPSSMASQARNWVPGPSYRQQRVSTTTNQNNNSNFAWTGAAKFKLNGRDSLMNPGVAMASHKDDDDRFFPSSGVLIFGKQGAGNDGVDYSQVLITDEEEIKATNPVATEEYGAVAINNQAANTQAQTGLVHNQGVIPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPLTFNQAKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGVYSEPRPIGTRYLTRNL
MASGGGAPMADNNEGADGVGNSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNEGTKTIANNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMVPQYGYLTLNNGSQALGRSSFYCLEYFPSQMLRTGNNFQFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLVRTQTTGTGGTQTLAFSQAGPSSMASQARNWVPGPSYRQQRVSTTTNQNNNSNFAWTGAAKFKLNGRDSLMNPGVAMASHKDDDDRFFPSSGVLIFGKQGAGNDGVDYSQVLITDEEEIKATNPVATEEYGAVAINNQAANTQAQTGLVHNQGVIPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPLTFNQAKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGVYSEPRPIGTRYLTRNL
ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTGGGACTTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGGTGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCGGACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCTGCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCTAAGACGGCTCCTGGAAAGAAGAGACCGGTAGAGCAGTCACCCCAAGAACCAGACTCCTCATCGGGCATCGGCAAGACAGGCCAGCAGCCCGCTAAAAAGAGACTCAATTTTGGTCAGACTGGCGACACAGAGTCAGTCCCCGACCCACAACCTCTCGGAGAACCTCCAGCAGCCCCCTCAGGTCTGGGACCTAATACAATGGCTTCAGGCGGTGGCGCTCCAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAATTCCTCGGGAAATTGGCATTGCGATTCCACATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAACGGCACCTCGGGAGGAAGCACCAACGACAACACCTACTTTGGCTACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTTTCACCACGTGACTGGCAGCGACTCATCAACAACAATTGGGGATTCCGGCCCAAGAGACTCAACTTCAAGCTCTTCAACATCCAGGTCAAGGAAGTCACGACGAACGAAGGCACCAAGACCATCGCCAATAATCTCACCAGCACCGTGCAGGTCTTTACGGACTCGGAGTACCAGCTACCGTACGTGCTAGGATCAGCTCACCAGGGATGTCTGCCTCCGTTCCCGGCGGACGTCTTCATGGTTCCTCAGTACGGTTATCTAACTCTGAACAATGGCAGCCAGGCCCTGGGACGTTCCTCCTTCTACTGCCTGGAGTATTTCCCATCGCAGATGCTGAGAACCGGCAACAACTTTCAGTTCAGCTACACCTTCGAGGACGTGCCTTTCCACAGCAGCTACGCGCACAGCCAAAGCCTGGACAGGCTGATGAATCCCCTCATCGACCAGTACCTGTATTACCTGGTCAGAACGCAGACAACCGGGACTGGAGGGACGCAGACTCTGGCATTCAGCCAAGCAGGCCCTAGCTCAATGGCCAGCCAGGCTAGAAACTGGGTGCCCGGACCGAGCTACCGGCAGCAGCGCGTCTCCACGACAACCAACCAGAACAACAACAGCAACTTTGCCTGGACGGGAGCTGCCAAATTTAAACTGAACGGCCGAGACTCTCTAATGAACCCCGGCGTGGCCATGGCTTCACACAAGGATGACGATGACCGGTTCTTCCCTTCTAGCGGGGTCCTGATTTTCGGCAAGCAAGGAGCCGGGAATGATGGAGTGGATTACAGCCAAGTGCTGATTACAGATGAGGAAGAAATCAAGGCTACCAACCCCGTGGCAACAGAGGAATATGGAGCAGTGGCCATCAACAACCAGGCCGCTAATACGCAGGCGCAGACCGGACTCGTGCACAACCAGGGGGTGATTCCCGGCATGGTGTGGCAGAACAGAGACGTGTACCTGCAGGGTCCCATCTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCGTCTCCCCTGATGGGCGGCTTTGGACTGAAGCACCCGCCTCCTCAAATTCTCATCAAGAACACACCGGTTCCAGCGGACCCGCCGCTTACCTTCAACCAGGCCAAGCTGAACTCTTTCATCACGCAGTACAGCACCGGACAGGTCAGCGTGGAAATCGAGTGGGAGCTGCAGAAAGAAAACAGCAAACGCTGGAATCCAGAGATTCAGTACACTTCCAACTACTACAAATCTACAAATGTGGACTTTGCTGTCAACACGGAAGGAGTGTATAGCGAGCCTCGCCCCATTGGCACGCGCTACCTCACCCGTAATCTGTAA
ACGGCTCCTGGAAAGAAGAGACCGGTAGAGCAGTCACCCCAAGAACCAGACTCCTCATCGGGCATCGGCAAGACAGGCCAGCAGCCCGCTAAAAAGAGACTCAATTTTGGTCAGACTGGCGACACAGAGTCAGTCCCCGACCCACAACCTCTCGGAGAACCTCCAGCAGCCCCCTCAGGTCTGGGACCTAATACAATGGCTTCAGGCGGTGGCGCTCCAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAATTCCTCGGGAAATTGGCATTGCGATTCCACATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAACGGCACCTCGGGAGGAAGCACCAACGACAACACCTACTTTGGCTACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTTTCACCACGTGACTGGCAGCGACTCATCAACAACAATTGGGGATTCCGGCCCAAGAGACTCAACTTCAAGCTCTTCAACATCCAGGTCAAGGAAGTCACGACGAACGAAGGCACCAAGACCATCGCCAATAATCTCACCAGCACCGTGCAGGTCTTTACGGACTCGGAGTACCAGCTACCGTACGTGCTAGGATCAGCTCACCAGGGATGTCTGCCTCCGTTCCCGGCGGACGTCTTCATGGTTCCTCAGTACGGTTATCTAACTCTGAACAATGGCAGCCAGGCCCTGGGACGTTCCTCCTTCTACTGCCTGGAGTATTTCCCATCGCAGATGCTGAGAACCGGCAACAACTTTCAGTTCAGCTACACCTTCGAGGACGTGCCTTTCCACAGCAGCTACGCGCACAGCCAAAGCCTGGACAGGCTGATGAATCCCCTCATCGACCAGTACCTGTATTACCTGGTCAGAACGCAGACAACCGGGACTGGAGGGACGCAGACTCTGGCATTCAGCCAAGCAGGCCCTAGCTCAATGGCCAGCCAGGCTAGAAACTGGGTGCCCGGACCGAGCTACCGGCAGCAGCGCGTCTCCACGACAACCAACCAGAACAACAACAGCAACTTTGCCTGGACGGGAGCTGCCAAATTTAAACTGAACGGCCGAGACTCTCTAATGAACCCCGGCGTGGCCATGGCTTCACACAAGGATGACGATGACCGGTTCTTCCCTTCTAGCGGGGTCCTGATTTTCGGCAAGCAAGGAGCCGGGAATGATGGAGTGGATTACAGCCAAGTGCTGATTACAGATGAGGAAGAAATCAAGGCTACCAACCCCGTGGCAACAGAGGAATATGGAGCAGTGGCCATCAACAACCAGGCCGCTAATACGCAGGCGCAGACCGGACTCGTGCACAACCAGGGGGTGATTCCCGGCATGGTGTGGCAGAACAGAGACGTGTACCTGCAGGGTCCCATCTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCGTCTCCCCTGATGGGCGGCTTTGGACTGAAGCACCCGCCTCCTCAAATTCTCATCAAGAACACACCGGTTCCAGCGGACCCGCCGCTTACCTTCAACCAGGCCAAGCTGAACTCTTTCATCACGCAGTACAGCACCGGACAGGTCAGCGTGGAAATCGAGTGGGAGCTGCAGAAAGAAAACAGCAAACGCTGGAATCCAGAGATTCAGTACACTTCCAACTACTACAAATCTACAAATGTGGACTTTGCTGTCAACACGGAAGGAGTGTATAGCGAGCCTCGCCCCATTGGCACGCGCTACCTCACCCGTAATCTGTAA
GGGCCCCAGAAGCCTGGTGGTTGTTTGTCCTTCTCAGGGGAAAAGTGAGGCGGCCCCTTGGAGGAAGGGGCCGGGCAGAATGATCTAATCGGATTCCAAGCAGCTCAGGGGATTGTCTTTTTCTAGCACCTTCTTGCCACTCCTAAGCGTCCTCCGTGACCCCGGCTGGGATTTAGCCTGGTGCTGTGTCAGCCCCGGTCTCCCAGGGGCTTCCCAGTGGTCCCCAGGAACCCTCGACAGGGCCCGGTCTCTCTCGTCCAGCAAGGGCAGGGACGGGCCACAGGCCAAGGGC (配列番号11)
ATGACCGCCTGCGCCCGCCGAGCGGGTGGGCTTCCGGACCCCGGGCTCTGCGGTCCCGCGTGGTGGGCTCCGTCCCTGCCCCGCCTCCCCCGGGCCCTGCCCCGGCTCCCGCTCCTGCTGCTCCTGCTTCTGCTGCAGCCCCCCGCCCTCTCCGCCGTGTTCACGGTGGGGGTCCTGGGCCCCTGGGCTTGCGACCCCATCTTCTCTCGGGCTCGCCCGGACCTGGCCGCCCGCCTGGCCGCCGCCCGCCTGAACCGCGACCCCGGCCTGGCAGGCGGTCCCCGCTTCGAGGTAGCGCTGCTGCCCGAGCCTTGCCGGACGCCGGGCTCGCTGGGGGCCGTGTCCTCCGCGCTGGCCCGCGTGTCGGGCCTCGTGGGTCCGGTGAACCCTGCGGCCTGCCGGCCAGCCGAGCTGCTCGCCGAAGAAGCCGGGATCGCGCTGGTGCCCTGGGGCTGCCCCTGGACGCAGGCGGAGGGCACCACGGCCCCTGCCGTGACCCCCGCCGCGGATGCCCTCTACGCCCTGCTTCGCGCATTCGGCTGGGCGCGCGTGGCCCTGGTCACCGCCCCCCAGGACCTGTGGGTGGAGGCGGGACGCTCACTGTCCACGGCACTCAGGGCCCGGGGCCTGCCTGTCGCCTCCGTGACTTCCATGGAGCCCTTGGACCTGTCTGGAGCCCGGGAGGCCCTGAGGAAGGTTCGGGACGGGCCCAGGGTCACAGCAGTGATCATGGTGATGCACTCGGTGCTGCTGGGTGGCGAGGAGCAGCGCTACCTCCTGGAGGCCGCAGAGGAGCTGGGCCTGACCGATGGCTCCCTGGTCTTCCTGCCCTTCGACACGATCCACTACGCCTTGTCCCCAGGCCCGGAGGCCTTGGCCGCACTCGCCAACAGCTCCCAGCTTCGCAGGGCCCACGATGCCGTGCTCACCCTCACGCGCCACTGTCCCTCTGAAGGCAGCGTGCTGGACAGCCTGCGCAGGGCTCAAGAGCGCCGCGAGCTGCCCTCTGACCTCAATCTGCAGCAGGTCTCCCCACTCTTTGGCACCATCTATGACGCGGTCTTCTTGCTGGCAAGGGGCGTGGCAGAAGCGCGGGCTGCCGCAGGTGGCAGATGGGTGTCCGGAGCAGCTGTGGCCCGCCACATCCGGGATGCGCAGGTCCCTGGCTTCTGCGGGGACCTAGGAGGAGACGAGGAGCCCCCATTCGTGCTGCTAGACACGGACGCGGCGGGAGACCGGCTTTTTGCCACATACATGCTGGATCCTGCCCGGGGCTCCTTCCTCTCCGCCGGTACCCGGATGCACTTCCCGCGTGGGGGATCAGCACCCGGACCTGACCCCTCGTGCTGGTTCGATCCAAACAACATCTGCGGTGGAGGACTGGAGCCGGGCCTCGTCTTTCTTGGCTTCCTCCTGGTGGTTGGGATGGGGCTGGCTGGGGCCTTCCTGGCCCATTATGTGAGGCACCGGCTACTTCACATGCAAATGGTCTCCGGCCCCAACAAGATCATCCTGACCGTGGACGACATCACCTTTCTCCACCCACATGGGGGCACCTCTCGAAAGGTGGCCCAGGGGAGTCGATCAAGTCTGGGTGCCCGCAGCATGTCAGACATTCGCAGCGGCCCCAGCCAACACTTGGACAGCCCCAACATTGGTGTCTATGAGGGAGACAGGGTTTGGCTGAAGAAATTCCCAGGGGATCAGCACATAGCTATCCGCCCAGCAACCAAGACGGCCTTCTCCAAGCTCCAGGAGCTCCGGCATGAGAACGTGGCCCTCTACCTGGGGCTTTTCCTGGCTCGGGGAGCAGAAGGCCCTGCGGCCCTCTGGGAGGGCAACCTGGCTGTGGTCTCAGAGCACTGCACGCGGGGCTCTCTTCAGGACCTCCTCGCTCAGAGAGAAATAAAGCTGGACTGGATGTTCAAGTCCTCCCTCCTGCTGGACCTTATCAAGGGAATAAGGTATCTGCACCATCGAGGCGTGGCTCATGGGCGGCTGAAGTCACGGAACTGCATAGTGGATGGCAGATTCGTACTCAAGATCACTGACCACGGCCACGGGAGACTGCTGGAAGCACAGAAGGTGCTACCGGAGCCTCCCAGAGCGGAGGACCAGCTGTGGACAGCCCCGGAGCTGCTTAGGGACCCAGCCCTGGAGCGCCGGGGAACGCTGGCCGGCGACGTCTTTAGCTTGGCCATCATCATGCAAGAAGTAGTGTGCCGCAGTGCCCCTTATGCCATGCTGGAGCTCACTCCCGAGGAAGTGGTGCAGAGGGTGCGGAGCCCCCCTCCACTGTGTCGGCCCTTGGTGTCCATGGACCAGGCACCTGTCGAGTGTATCCTCCTGATGAAGCAGTGCTGGGCAGAGCAGCCGGAACTTCGGCCCTCCATGGACCACACCTTCGACCTGTTCAAGAACATCAACAAGGGCCGGAAGACGAACATCATTGACTCGATGCTTCGGATGCTGGAGCAGTACTCTAGTAACCTGGAGGATCTGATCCGGGAGCGCACGGAGGAGCTGGAGCTGGAAAAGCAGAAGACAGACCGGCTGCTTACACAGATGCTGCCTCCGTCTGTGGCTGAGGCCTTGAAGACGGGGACACCAGTGGAGCCCGAGTACTTTGAGCAAGTGACACTGTACTTTAGTGACATTGTGGGCTTCACCACCATCTCTGCCATGAGTGAGCCCATTGAGGTTGTGGACCTGCTCAACGATCTCTACACACTCTTTGATGCCATCATTGGTTCCCACGATGTCTACAAGGTGGAGACAATAGGGGACGCCTATATGGTGGCCTCGGGGCTGCCCCAGCGGAATGGGCAGCGACACGCGGCAGAGATCGCCAACATGTCACTGGACATCCTCAGTGCCGTGGGCACTTTCCGCATGCGCCATATGCCTGAGGTTCCCGTGCGCATCCGCATAGGCCTGCACTCGGGTCCATGCGTGGCAGGCGTGGTGGGCCTCACCATGCCGCGGTACTGCCTGTTTGGGGACACGGTCAACACCGCCTCGCGCATGGAGTCCACCGGGCTGCCTTACCGCATCCACGTGAACTTGAGCACTGTGGGGATTCTCCGTGCTCTGGACTCGGGCTACCAGGTGGAGCTGCGAGGCCGCACGGAGCTGAAGGGCAAGGGCGCCGAGGACACTTTCTGGCTAGTGGGCAGACGCGGCTTCAACAAGCCCATCCCCAAACCGCCTGACCTGCAACCGGGGTCCAGCAACCACGGCATCAGCCTGCAGGAGATCCCACCCGAGCGGCGACGGAAGCTGGAGAAGGCGCGGCCGGGCCAGTTCTCTTGA (配列番号9)
ATGAGCGCTTGGCTCCTGCCAGCCGGAGGGCTTCCCGGCGCCGGGTTCTGTGTCCCTGCGCGGCAGTCTCCGTCCAGTTTCTCGCGGGTCCTGCGCTGGCCAAGGCCTGGGCTACCGGGACTCCTGCTACTGCTACTGCTCCCATCTCCTTCTGCCCTCTCTGCTGTGTTCAAAGTGGGGGTGCTGGGCCCCTGGGCTTGCGACCCCATCTTTGCACGGGCCCGACCAGACCTGGCTGCGCGTCTGGCCGCCAACCGCCTGAATCGTGACTTTGCTTTAGACGGCGGCCCCCGGTTCGAGGTTGCGCTGCTCCCAGAGCCCTGCCTGACTCCGGGCTCACTAGGGGCTGTGTCCTCTGCGCTGTCTCGAGTCTCTGGCCTGGTGGGTCCGGTGAACCCCGCAGCCTGTCGGCCAGCCGAACTGTTGGCTCAAGAAGCTGGAGTAGCGCTGGTGCCCTGGGGCTGCCCTGGCACGCGGGCGGCGGGTACTACAGCCCCGGCGGTGACCCCCGCTGCAGATGCTCTCTACGTCCTCCTTAGAGCATTCCGCTGGGCGCGCGTGGCCCTGATCACTGCACCCCAAGACCTGTGGGTGGAGGCGGGACGCGCTCTGTCCACAGCACTCAGGGCCCGGGGTTTGCCAGTTGCCCTAGTGACTTCCATGGAGACTTCAGACCGGTCTGGAGCCCGGGAGGCCCTCGGGAGGATCCGAGATGGGCCTAGAGTTAGAGTAGTGATCATGGTGATGCACTCGGTGCTGCTGGGCGGCGAGGAGCAGCGCTACCTACTGGAAGCTGCAGAAGAACTGGCTCTGACTGATGGCTCCCTGGTTTTCCTGCCCTTCGACACGCTTCACTACGCTTTGTCTCCAGGCCCGGAGGCTCTGGCTGCATTTGTCAACAGCTCCCAGCTCCGCAGGGCTCACGATGCGGTGCTCACACTCACGCGCCGCTGTCCTCCTGGAGGCAGCGTGCAAGACAGCCTGCGCAGGGCTCAAGAACACCAGGAACTGCCCCTTGACCTCAACCTGAAGCAGGTCTCTCCGCTGTTTGGCACCATCTATGATGCTGTCTTCCTGTTGGCTGGGGGCGTGAAGAGAGCAAGAACAGCGGTGGGTGGTGGCTGGGTGTCAGGTGCATCTGTAGCCCGCCAAGTACGGGAAGCACAAGTCTCTGGCTTTTGTGGGGTCCTGGGAAGAACCGAGGAGCCCTCCTTTGTGCTGCTGGACACAGATGCATCCGGAGAACAGTTGTTCGCAACACACCTGCTAGATCCTGTCTTAGGCTCCCTGCGTTCTGCAGGGACCCCCATGCACTTCCCTAGAGGTGGACCTGCCCCGGGACCAGACCCTTCCTGCTGGTTCGATCCAGATGTGATCTGCAACGGAGGGGTGGAGCCAGGCCTGGTCTTTGTTGGCTTCCTCCTGGTGATAGGGATGGGACTGACTGGAGCCTTCTTGGCTCATTACTTGAGGCACAGGCTGCTACACATGCAGATGGCTTCCGGCCCCAACAAGATCATCTTGACGTTGGAAGATGTTACTTTCCTCCACCCACCGGGAGGCAGCTCTCGAAAGGTGGTCCAGGGAAGTAGATCCAGTCTGGCTACCCGGAGCGCATCAGACATTCGCAGTGTCCCCAGCCAGCCCCAAGAGAGCACCAACGTTGGCCTCTATGAGGGGGACTGGGTTTGGCTGAAGAAGTTCCCAGGGGAACATCATATGGCTATCAGGCCAGCAACAAAGACAGCCTTCTCCAAGCTTCGAGAGCTCCGGCATGAGAATGTGGCTCTCTACTTGGGACTCTTCCTGGCGGGTACAGCAGACAGCCCTGCCACCCCTGGGGAGGGCATCTTGGCTGTGGTCTCAGAGCACTGTGCTCGGGGTTCCCTCCATGACCTCCTGGCCCAGAGAGAAATAAAGCTGGACTGGATGTTCAAGTCTTCCCTCCTGCTGGACCTCATCAAGGGAATGAGATATCTGCACCATCGCGGTGTGGCCCACGGGAGGCTCAAGTCACGGAATTGCGTGGTGGACGGGAGGTTCGTGCTCAAGGTGACAGATCATGGCCATGGGCGACTGCTGGAAGCGCAAAGGGTGTTACCGGAACCTCCCAGTGCAGAGGATCAGCTATGGACAGCCCCAGAGCTTCTTCGGGACCCCTCCCTGGAGCGCCGGGGAACTCTAGCTGGTGATGTCTTTAGTCTGGCCATCATCATGCAGGAGGTCGTGTGCCGCAGCACCCCTTATGCCATGCTGGAACTAACGCCCGAGGAAGTAATACAGAGGGTGCGGAGCCCTCCTCCACTGTGTCGGCCCTTGGTGTCCATGGACCAGGCACCCATGGAGTGCATCCAGCTGATGACACAATGCTGGGCAGAGCATCCAGAACTTCGGCCTTCCATGGACCTCACCTTTGACCTGTTCAAGAGCATCAACAAGGGCCGGAAGACCAACATCATCGACTCCATGCTTCGGATGCTGGAGCAGTACTCTAGTAACCTGGAGGATCTGATCCGAGAACGCACAGAGGAGTTAGAGCAGGAGAAGCAGAAGACAGACAGGCTGCTCACACAGATGCTGCCTCCATCTGTGGCTGAGGCCCTGAAGATGGGGACATCTGTGGAGCCTGAGTACTTTGAAGAGGTGACACTCTACTTCAGTGACATCGTGGGCTTTACCACCATTTCAGCCATGAGCGAGCCTATTGAGGTGGTAGACCTGCTTAATGACCTCTATACTCTCTTCGATGCCATCATCGGTGCCCATGATGTCTATAAGGTGGAAACAATTGGAGATGCATATATGGTGGCCTCCGGGCTGCCGCAGAGGAACGGGCAGCGGCACGCTGCAGAGATTGCCAACATGTCACTGGACATCCTCAGTGCAGTCGGCTCCTTCCGCATGCGCCATATGCCCGAGGTACCGGTGCGCATCCGCATTGGTTTGCACTCAGGCCCGTGCGTGGCGGGTGTGGTGGGCCTCACCATGCCTCGGTACTGCCTGTTCGGGGACACGGTCAACACTGCCTCGAGAATGGAGTCCACTGGACTGCCTTACCGCATCCACGTTAACATGAGCACTGTTCGGATTCTTCGCGCTCTGGACCAAGGCTTCCAGATGGAGTGTCGAGGCCGCACGGAGCTGAAGGGCAAGGGTATTGAGGACACGTACTGGCTTGTGGGCAGACTTGGCTTCAACAAGCCCATTCCCAAACCACCTGATCTGCAGCCAGGGGCCAGCAACCATGGTATCAGCCTGCAGGAGATTCCCCCAGAGAGACGCAAGAAGCTGGAGAAAGCCAGGCCAGGCCAGTTTACTGGGAAGTGA (配列番号10)
以下の例は、本発明の好ましい態様を実証するために包含される。当業者には、以下の例に開示される技法が、本発明の実施において良好に機能するものとして本発明者に発見された技法を表し、および、よって、その実施のための好ましい様式を構成すると考えてよいということが当然理解されるべきである。しかしながら、当業者は、本開示に照らして、開示された特定の態様には多くの変更がなされ、およびそれでもなお似たようなまたは類似の結果が本発明の精神および範囲から逸脱することなく得られてもよいということを当然理解すべきである。
硝子体内(Ivt)または網膜下(SR)注射の後に続いて、AAV44.9の網膜形質導入および指向性を評価した。全ての桿体光受容器におけるGFPの構成的発現を伴うマウスモデル(Nrl-GFP Sマウス)を利用することによって、AAV44.9ならびにベンチマークのカプシドAAV5およびAAV8(Y733F)について光受容器形質導入効率を定量化した。
AAVカプシド系統樹が、図1に示される。AAVについてのVP1アミノ酸配列を、ClustalW (AlignX-Vector NTI)を使用してアラインメントした。アラインメントを、次いで、EMBL-EBI Simple Phylogenyプログラム(ebi.ac.uk/Tools/phylogeny/simple_phylogeny/)を使用した近隣結合法を介して系統樹を生成するために使用した。結果としてもたらされたツリーを、TreeViewプログラムを使用して視覚化し、および、AAV5を外群として指定した。
二段積みセルファクトリー中に播種された接着性HEK293T(1,272cm2細胞増殖面積)においてトリプルトランスフェクションプラスミドに基づいた系を使用して、短縮キメラCMV-ニワトリベータアクチン(smCBA)プロモーター駆動mCherryを含有する自己相補的AAVコンストラクト(sc-smCBA-mCherry)をAAV44.9、AAV5およびAAV8(Y733F)中へとパッケージングさせた。細胞を収穫し、および連続的な凍結融解サイクルによって溶解させた。溶解物中のウイルスをイオジキサノール密度勾配によって精製し、および、Tween 20(0.014%)添加Alcon BSSへと緩衝液交換した。ウイルスを、標準に対して相対的にqPCRによって力価決定し、および-80℃で保管した。Y733FおよびE531D置換を加えることは、AAV2rep-44.9capプラスミドの部位指定突然変異誘発によって成し遂げられ、およびサンガーシーケンシングによって確認された。錐体特異的なRBPe-GNAT2キメラプロモーター駆動緑色蛍光タンパク質(GFP)を含有するさらなるコンストラクトを、AAV44.9中にパッケージングさせた。
ARPE-19(ヒト網膜色素上皮細胞株)および661W(マウス錐体細胞株)細胞を、96ウェルプレート中に1.0×104細胞/ウェルの濃度で播種した。翌日、細胞を、10,000p/細胞で感染させた。感染3日後、固定された露光での蛍光顕微鏡検査を行い、細胞を切り離し、および、蛍光を介してレポータータンパク質発現(mCherry)を定量化するためにフローサイトメトリーを使用した。平均mCherry蛍光に陽性細胞の数を乗算することによってmCherry発現を算出した。グラフは、発現レベルから細胞のみのレベルを差し引いたものを表す。
1μl中の2×109vgのベクター含有溶液を、硝子体内または網膜下のいずれかで4~5週齢Nrl-GFPおよびC57BL/6Jマウスに送達させた。各実験において、成功した注射を受けた最低6つの眼を分析した。
注射4週間後に、Micron IIIカメラ(Phoenix Research Laboratories, Pleasanton, CA)を使用した眼底検査を行った。明視野および赤色蛍光像を、それぞれ網膜の健康状態およびmCherry発現を視覚化するために取った。露光設定は実験間で一定であり、および図の凡例に示される。
コホートあたり4~6のNrl-GFPの眼から神経網膜(網膜から手作業でRPEを剥ぎ取った)を収穫し、および、パパインで解離させた。処置され解離させられた網膜および未処置の対照について、GFPに対して陽性であった細胞(桿体光受容器)、mCherryに対して陽性であった細胞(rAAVによって形質導入された非桿体網膜ニューロン)、または両方に対して陽性であった細胞(rAAVによって形質導入された桿体光受容器)の割合を定量化するためにフローサイトメトリーを行った。各ベクターによって形質導入された桿体および非桿体神経網膜細胞の割合を、別々に平均した。
注射4週間後、眼を除核し、新たに調製したリン酸緩衝生理食塩水(PBS)中4%パラホルムアルデヒド(PFA)中で終夜4℃にて固定した。角膜と水晶体を除去し、および、眼杯(eye cup)を30%スクロース溶液中で終夜4℃にてインキュベートした。眼をクライオスタットコンパウンド中に埋め込み、および-80℃にて凍結させた。クライオスタット(Leica Microsystem, Buffalo Grove, IL)を使用して切片(厚さ12μm)を切り取り、およびガラススライドへ移した。網膜凍結切片を1×リン酸緩衝生理食塩水(PBS)で洗い流し、0.5%Triton-X100および1%ウシ血清アルブミン(BSA)を用いて各1時間ブロッキングし、および次いでマウスモノクローナル抗錐体アレスチン抗体(1:1000、Dr Clay Smithによりご厚意で提供された)を用いて終夜4℃にてインキュベートした。翌日、スライドを1×PBSで洗い流し、および次いで1×PBS中のAlexa Fluorロバ抗マウス二次抗体(1:500)を用いて1時間室温にてインキュベートし、およびDAPIで対比染色した。共焦点レーザー顕微鏡(Leica TCS SP8)および蛍光顕微鏡(EVOS)を使用して画像を取得した。
AAV44.9による桿体の形質導入は、ベンチマークのベクターAAV5およびAAV8(Y733F)のそれよりも大きい
網膜下注射の4週間でのAAV44.9、AAV5およびAAV8(Y733F)の質的および量的分析が、図2A~2Eに示される。図2Eに描かれたFACSデータは、2×109vgでの網膜下注射の後に続いてAAV5およびAAV8(Y733F)よりもAAV44.9の方がより効率的に桿体を形質導入させたということを示す。AAV5、AAV8(Y733F)、およびAAV44.9を注射されたNrl-GFPマウス網膜における光受容器およびRPEにおけるmCherry発現を示す代表的な網膜横断面像が、網膜下注射の4週間後での図3A~3Cに示される。
Nrl-GFPマウスの代表的な眼底像(赤色蛍光フィルター)を、AAV44.9またはAAV44.9(E531D)での網膜下注射4週間後に取った(図9Aを参照)。ベクターは、1μL中の2×109vgで送達された。露光およびゲインの設定は、実験の間にわたって一貫していた。実験は、結果を確認するために2回繰り返された。「繰り返し」実験は異なるロットのウイルスを用いて行われたということに留意されたい。
ヒトロドプシンキナーゼ(hGRK1)プロモーターが、非ヒト霊長類の錐体および桿体において専用の活性を有するということが、以前に決定された。ひいては、改善されたAAV44.9(E531D)ベクターにおいて、マカクの眼におけるGFPレポーター発現を駆り立てるその能力についてhGRK1プロモーターを評価した。当初のブレブ境界からの側方への広がりの度合いもまた評価した。
以前の例は、改善されたAAV44.9(E531D)ベクターによって送達されたレポーター遺伝子の中心窩形質導入を実証した。興味の対象の治療用ペプチドをコードする改善されたAAV44.9(E531D)ベクターの投与の後に続く、側方への広がりの度合いを、次に決定した。選択された興味の対象の治療用ペプチドは、ヒトグアニル酸シクラーゼ2DであるGUCY2Dのマウスホモログ、Gucy2eであった。
本明細書に記載の例および態様は例証目的のためのみのものであり、ならびに、それらに照らして様々な改良または変更が当業者に示唆され得、そして本出願および添付の請求の範囲の精神および視野の内に包含されることとなる、ということが理解されるべきである。本明細書に引用されている出版物、特許出願および出願を含む全ての参考文献は、各参考文献が参照により援用されることが個別かつ具体的に示されかつ本明細書中にそれら全体が規定されたとした場合と同程度に参照により本明細書に援用される。本明細書中の値の範囲の記述は、本明細書に別様に示されていない限り、該範囲内にある各々の別々の値に個別に言及する簡単な方法としての役割を果たすことを意図したものにすぎず、および、各々の別々の値は、それが個別に本明細書に記述されていたかのように明細書中へと援用される。
Claims (25)
- 配列番号3のアミノ酸配列を含むカプシドタンパク質を含む、組換えアデノ随伴ウイルス(rAAV)粒子であって、異種核酸配列を含むポリヌクレオチドをさらに含む、前記rAAV粒子。
- 異種核酸配列が、光受容細胞または網膜色素上皮細胞における該異種核酸配列の発現を指揮する調節配列に作動可能に連結している、請求項1に記載のrAAV粒子。
- 異種核酸配列が、1以上の逆方向末端反復(ITR)配列に隣接している、請求項1または2に記載のrAAV粒子。
- VP1、VP2、およびVP3カプシドタンパク質を含み、ここで、VP1タンパク質は、配列番号1のアミノ酸配列を含む、VP2タンパク質は、配列番号2のアミノ酸配列を含む、および/または、VP3タンパク質は、配列番号3のアミノ酸配列を含む、請求項1~3のいずれか一項に記載のrAAV粒子。
- ポリヌクレオチドが、哺乳動物の目の1以上の光受容細胞または網膜色素上皮細胞において核酸配列を発現させることを可能とするプロモーターに作動可能に連結している診断または治療剤をコードする異種核酸配列を含む、請求項1~4のいずれか一項に記載のrAAV粒子。
- 異種核酸配列が、ポリペプチド、ペプチド、リボザイム、ペプチド核酸、siRNA、RNAi、アンチセンスオリゴヌクレオチド、アンチセンスポリヌクレオチド、抗体、抗原結合フラグメント、またはそれらのいずれかの組み合わせをコードする、請求項5に記載のrAAV粒子。
- 異種核酸配列が、ヒトロドプシンキナーゼ(hGRK1)プロモーターに作動可能に連結している、請求項1~6のいずれか一項に記載のrAAV粒子。
- 請求項1~7のいずれか一項に記載のrAAV粒子を含み、1以上の薬学的に許容し得る担体、緩衝液、希釈剤または賦形剤をさらに含む、組成物。
- 配列番号1、2、および/または3のアミノ酸配列を含む、カプシドタンパク質。
- 配列番号4、5、および/または6の核酸配列を含む、核酸。
- プラスミドまたはウイルスベクターの中に含まれている、請求項10に記載の核酸。
- 請求項9に記載のカプシドタンパク質または請求項10に記載の核酸を含む、細胞。
- 哺乳動物または昆虫の細胞である、請求項12に記載の細胞。
- 哺乳動物の光受容細胞または網膜色素上皮細胞を形質導入させるための方法であって、請求項1~7のいずれか一項に記載のrAAV粒子または請求項8に記載の組成物を哺乳動物の片目または両目に投与することを含む、前記方法。
- 選択された治療剤の治療有効量を、それを必要とする哺乳動物に提供するための方法であって、請求項1~7のいずれか一項に記載のrAAV粒子または請求項8に記載の組成物を、該選択された治療剤の治療有効量を該哺乳動物に提供するのに有効な量および時間にて、哺乳動物の片目または両目に投与することを含む、前記方法。
- 哺乳動物における疾患、障害、機能不全、損傷、状態、または外傷の症状を処置するかまたは和らげるための方法であって、請求項1~7のいずれか一項に記載のrAAV粒子または請求項8に記載の組成物を、哺乳動物における疾患、障害、機能不全、損傷、状態、または外傷の症状を処置するかまたは和らげるのに十分な量および時間にて、それを必要とする哺乳動物の片目または両目に網膜下もしくは硝子体内投与することを含む、前記方法。
- 哺乳動物の1以上の光受容細胞またはRPE細胞において核酸セグメントを発現させるための方法であって:哺乳動物の1以上のPR細胞またはRPE細胞において治療剤を生産するのに有効な時間の間、請求項1~7のいずれか一項に記載のrAAV粒子または請求項8に記載の組成物を哺乳動物の片目または両目に網膜下もしくは硝子体内投与することを含む、ここでrAAV粒子は、少なくとも治療剤をコードする第1の異種核酸配列に作動可能に連結しているPRもしくはRPE細胞特異的プロモーターを含む少なくとも第1のポリヌクレオチドを含んだポリヌクレオチドを含む、前記方法。
- 哺乳動物が、ヒトである、請求項14~17のいずれか一項に記載の方法。
- ヒトが、網膜障害、網膜疾患、網膜ジストロフィー、またはそれらのいずれかの組み合わせを有するか、それを有する疑いがあるか、それを発症するリスクがあるか、またはそれと診断されている、請求項18に記載の方法。
- 治療剤の生産が、a)1以上の光受容細胞または1以上のRPE細胞を保存する、b)桿体および/もしくは錐体に媒介される1以上の機能を修復する、c)片目または両目において視覚挙動を修復する、またはd)これらのいずれかの組み合わせとなる、請求項19に記載の方法。
- 哺乳動物の片目または両目へのrAAV粒子の初回投与の後に続いて実質的に少なくとも3か月の期間の間、1以上の光受容細胞または1以上のRPE細胞において治療剤の生産が持続する、請求項20に記載の方法。
- 請求項1~7のいずれか一項に記載のrAAV粒子または請求項8に記載の組成物を哺乳動物の中心窩に網膜下投与することを含む、請求項14~21のいずれか一項に記載の方法。
- 中心窩の剥離が最小限に抑えられる、請求項22に記載の方法。
- 異種核酸配列が、GUCY2Dを含む、請求項1~7のいずれか一項に記載のrAAVベクター。
- 異種核酸配列が、配列番号9に規定された配列と少なくとも95%、少なくとも98%、または少なくとも99%同一であるヌクレオチド配列を含む、請求項1~7のいずれか一項に記載のrAAVベクター。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962795695P | 2019-01-23 | 2019-01-23 | |
US62/795,695 | 2019-01-23 | ||
PCT/US2020/014838 WO2020154535A1 (en) | 2019-01-23 | 2020-01-23 | Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022523050A true JP2022523050A (ja) | 2022-04-21 |
JPWO2020154535A5 JPWO2020154535A5 (ja) | 2023-02-06 |
Family
ID=71737005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021543230A Pending JP2022523050A (ja) | 2019-01-23 | 2020-01-23 | 合理的設計により増強された新規なaavウイルスによる網膜における高効率の形質導入および側方への広がり |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220133909A1 (ja) |
EP (1) | EP3914229A4 (ja) |
JP (1) | JP2022523050A (ja) |
CN (1) | CN113347962A (ja) |
AU (1) | AU2020212026A1 (ja) |
CA (1) | CA3125294A1 (ja) |
WO (1) | WO2020154535A1 (ja) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001527399A (ja) * | 1997-04-21 | 2001-12-25 | ユニバーシティ オブ フロリダ | 網膜疾患の処置のための材料および方法 |
JP5702519B2 (ja) * | 2005-04-07 | 2015-04-15 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Aavベクターの機能を上げる方法 |
CA2941640A1 (en) * | 2014-03-04 | 2015-09-11 | University Of Florida Research Foundation, Inc. | Improved raav vectors and methods for transduction of photoreceptors and rpe cells |
IL292951B1 (en) * | 2014-05-02 | 2024-06-01 | Genzyme Corp | AAV vectors for gene therapy in the central nervous system and retina |
JP6805174B2 (ja) * | 2015-05-12 | 2020-12-23 | アメリカ合衆国 | 神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むaav分離株及び融合タンパク質 |
US20170348387A1 (en) * | 2016-02-29 | 2017-12-07 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for nphp5 lca-ciliopathy |
IL305149A (en) * | 2016-07-26 | 2023-10-01 | Biomarin Pharm Inc | Novel adeno-associated virus capsid proteins |
CA3114549A1 (en) * | 2017-02-21 | 2018-08-30 | University Of Florida Research Foundation, Incorporated | Modified aav capsid proteins and uses thereof |
-
2020
- 2020-01-23 JP JP2021543230A patent/JP2022523050A/ja active Pending
- 2020-01-23 EP EP20744697.2A patent/EP3914229A4/en active Pending
- 2020-01-23 CA CA3125294A patent/CA3125294A1/en active Pending
- 2020-01-23 WO PCT/US2020/014838 patent/WO2020154535A1/en unknown
- 2020-01-23 US US17/425,292 patent/US20220133909A1/en active Pending
- 2020-01-23 CN CN202080010452.1A patent/CN113347962A/zh active Pending
- 2020-01-23 AU AU2020212026A patent/AU2020212026A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020154535A1 (en) | 2020-07-30 |
EP3914229A1 (en) | 2021-12-01 |
AU2020212026A1 (en) | 2021-07-22 |
US20220133909A1 (en) | 2022-05-05 |
CA3125294A1 (en) | 2020-07-30 |
CN113347962A (zh) | 2021-09-03 |
EP3914229A4 (en) | 2022-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170007720A1 (en) | Methods and compositions for gene delivery to on bipolar cells | |
JP2019506445A (ja) | パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質 | |
JP7289306B2 (ja) | 網膜障害を治療するための組成物及び方法 | |
US20210347834A1 (en) | Gene therapy vector for treating retinitis pigmentosa disease | |
CN112029773B (zh) | 编码bdnf的核酸及其应用 | |
CN111876432A (zh) | 一组肝靶向新型腺相关病毒的获得及其应用 | |
US20230265455A1 (en) | Improved aav-mediated x-linked retinoschisis therapies | |
US20220226507A1 (en) | Optimized gene therapy targeting retinal cells | |
WO2023284879A1 (en) | Modified aav capsid for gene therapy and methods thereof | |
JP2022523050A (ja) | 合理的設計により増強された新規なaavウイルスによる網膜における高効率の形質導入および側方への広がり | |
JP2023522883A (ja) | 神経学的障害を処置するための組成物および方法 | |
US20230338582A1 (en) | Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy | |
US20240067989A1 (en) | Compositions and Methods for Treating Retinal Disorders | |
WO2023230657A1 (en) | Modified adeno-associated virus capsid proteins and methods thereof | |
CN111849998A (zh) | 编码人卵黄状黄斑病蛋白1的核酸分子及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230123 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230123 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231222 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240520 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240614 |